Read More

Ikena Oncology Outlines Key Priorities and Provides Corporate Updates; Announces Workforce Reduction Of ~35%; Ended 2023 In Strong Financial Position With ~$175M In Cash; Runway Extended Into H2 2026

IK-930 optimized formulation now in the clinic; on track to deliver additional monotherapy data in 2H 2024 IK-595 first cohort treated and cleared safety evaluation windowFocused execution on core targeted oncology

IKNA